Overview
Tertiary hyperparathyroidism (THPT) typically arises in patients with chronic kidney disease (CKD) who have undergone kidney transplantation, often developing after prolonged secondary hyperparathyroidism. This condition is characterized by autonomous parathyroid gland hyperactivity, leading to persistent hypercalcemia and often multi-gland involvement. The clinical presentation can be diverse, ranging from subtle metabolic disturbances to overt complications such as bone erosions and cardiovascular issues. Early recognition and timely intervention are crucial to prevent long-term complications and improve patient outcomes. This guideline synthesizes evidence from various studies to provide a comprehensive overview of THPT, focusing on clinical presentation, diagnosis, management, complications, prognosis, and special considerations.
Clinical Presentation
Tertiary hyperparathyroidism (THPT) often presents with a spectrum of symptoms reflecting its systemic effects. A notable case involved a 42-year-old female who exhibited prominent erosions of the iliac articular surfaces on CT imaging, initially raising suspicion for sacroiliitis [PMID:41030038]. However, these findings are more indicative of metabolic bone disease secondary to hyperparathyroidism rather than inflammatory spondyloarthropathies, highlighting the importance of considering hyperparathyroidism in the differential diagnosis of sacroiliac joint changes in CKD patients. The variability in presentation timelines is evident, with the median time from transplant to THPT diagnosis ranging from 15 days to over 4 years [PMID:32541226]. This wide range underscores the unpredictable nature of THPT onset and the need for vigilant monitoring in post-transplant patients.
Hypertension is a common comorbidity in THPT patients, often preceding surgical intervention. In one study, all 11 patients included had a history of hypertension, with ten requiring an average of 1.6 antihypertensive medications [PMID:17025024]. This hypertension likely stems from chronic hypercalcemia and its effects on vascular tone and renal function. Additionally, patients may present with nonspecific symptoms such as fatigue, weakness, and polyuria, reflecting the metabolic disturbances caused by elevated calcium levels. Bone pain and fractures are also frequent due to the erosive effects of hyperparathyroidism on bone tissue.
Diagnosis
Diagnosing THPT involves a combination of clinical assessment and laboratory investigations, often complemented by imaging modalities. Elevated serum calcium and parathyroid hormone (PTH) levels are hallmark indicators, with mean preoperative serum calcium levels typically around 10.8 mg/dL and PTH levels around 328 pg/mL [PMID:32541226]. These markers help differentiate THPT from secondary hyperparathyroidism and other causes of hypercalcemia. Imaging plays a crucial role in localizing parathyroid lesions. Ultrasound and scintigraphy are commonly used techniques. Ultrasound identified 1-2 adenomas in 63% of cases and ≥3 adenomas in 18%, while scintigraphy showed 1-2 areas of discordant uptake in 61% of cases [PMID:33774689]. However, both modalities have limitations; ultrasound was negative in 18% of cases, and scintigraphy was negative in 11%, indicating that these imaging techniques may not always pinpoint all affected glands.
CT imaging can further complicate the diagnostic process by revealing widened joint spaces and irregular articular surfaces, particularly erosions on the iliac sides of sacroiliac joints [PMID:41030038]. These findings can mimic inflammatory spondyloarthropathies, necessitating careful differentiation. In clinical practice, a combination of biochemical markers and imaging studies, often guided by clinical suspicion, is essential for accurate diagnosis. Persistent elevated calcaemia over a year post-transplant, seen in 39 out of 392 patients, often prompts referral for further evaluation and potential parathyroidectomy [PMID:17025024].
Differential Diagnosis
When evaluating patients with CKD who present with sacroiliac joint changes, distinguishing THPT from inflammatory spondyloarthropathies is critical. The case of the 42-year-old female with prominent erosions initially suspected to be sacroiliitis underscores the importance of considering metabolic bone disease secondary to hyperparathyroidism [PMID:41030038]. Other differential diagnoses include primary hyperparathyroidism, malignancy-related hypercalcemia, and granulomatous diseases. Laboratory findings such as elevated PTH levels and characteristic imaging features help differentiate THPT from these conditions. Clinicians should also consider the temporal relationship between transplant and symptom onset, as THPT typically develops after prolonged secondary hyperparathyroidism post-transplant.
Management
The management of THPT primarily revolves around surgical intervention, particularly total parathyroidectomy (PTX), to address the underlying glandular hyperplasia or adenomas. The patient in the aforementioned case underwent total parathyroidectomy prior to rheumatologic evaluation, highlighting the efficacy of surgical intervention in mitigating complications [PMID:41030038]. Preoperative imaging, such as ultrasound and scintigraphy, can guide surgical planning but may not always accurately predict the extent of disease. For instance, adenomas visualized preoperatively were found to be larger on pathology compared to those not visualized, and imaging identified only 42.3% of ectopic glands [PMID:33774689]. Despite these limitations, surgical removal remains the definitive treatment.
Non-surgical management options, such as cinacalcet, are used in some cases, especially when surgery is contraindicated or delayed. However, delays in referral for parathyroidectomy can impact outcomes. In a retrospective review, the median time to referral was 320 days, with over 50% of delays attributed to challenges with cinacalcet use [PMID:32541226]. Post-PTX, patients generally experience significant normalization of serum calcium levels, with mean levels dropping to 9.28 mg/dL compared to 10.20 mg/dL with cinacalcet [PMID:22706321]. Additionally, PTX leads to a higher resolution rate of hypercalcemic symptoms, with no patients experiencing persistent symptoms post-surgery compared to 25% in the observation group and 7.7% in the cinacalcet group [PMID:22706321].
In a study of 11 patients undergoing PTX after kidney transplantation, normalization of calcaemia was observed in all cases, accompanied by transient declines in blood pressure, though no significant changes in creatinine clearance were noted [PMID:17025024]. This underscores the importance of timely surgical intervention not only for metabolic control but also for cardiovascular stability. However, caution is advised as rare cases of transient deterioration in kidney function have been reported, affecting 2 out of 11 patients [PMID:17025024].
Complications
THPT can lead to several complications, including significant bone erosions that mimic inflammatory spondyloarthropathies, complicating diagnosis and management [PMID:41030038]. While PTX effectively normalizes hypercalcemia, there is a small risk of transient complications. Notably, two out of eleven patients experienced a slight deterioration in transplanted kidney excretory function, with borderline significant GFR decline noted 12 months post-PTX [PMID:17025024]. However, long-term renal function outcomes are generally favorable, with no significant differences in serum creatinine levels observed between PTX and other treatment modalities one year post-treatment [PMID:22706321]. Complication rates vary, with PTX showing the lowest incidence compared to medical management [PMID:22706321].
Prognosis & Follow-up
The prognosis for patients undergoing PTX for THPT is generally favorable, with high rates of eucalcemia post-surgery. In a review of 113 patients, 94.1% achieved eucalcemia at last follow-up, averaging 5.8 ± 3.6 years post-surgery [PMID:33774689]. Timely intervention appears to confer additional benefits, as patients referred for parathyroidectomy within 278 days post-diagnosis showed a 27.6% improvement in creatinine levels compared to those referred later [PMID:32541226]. Blood pressure values typically return to baseline levels within six to twelve months post-PTX, despite transient declines immediately following surgery [PMID:17025024]. Regular follow-up is essential to monitor calcium levels, renal function, and bone health, ensuring sustained remission and addressing any late complications promptly.
Special Populations
Understanding the specific characteristics of THPT in different patient subgroups is crucial. Among the 113 patients reviewed, 19 (17%) had single adenomas, 16 (14%) had double adenomas, and 69% exhibited multi-gland disease [PMID:33774689]. This distribution highlights the variability in disease presentation and underscores the need for tailored surgical approaches. Post-transplant patients, in particular, require close monitoring due to their unique risk factors and the potential impact on graft function. The prevalence of multi-gland disease emphasizes the importance of thorough preoperative imaging to guide surgical strategy effectively.
Key Recommendations
These recommendations aim to optimize patient outcomes by balancing timely intervention with comprehensive post-treatment care, addressing both the immediate and long-term implications of THPT.
References
1 Ferreira-Campinho C, Gonçalves H, Pereira P, Correia AM, Silva JL. Severe tertiary hyperparathyroidism as a rare mimicker of sacroiliitis. ARP rheumatology 2025. link 2 Berger MG, Pandian TK, Lyden ML, McKenzie T, Drake MT, Dy BM. Preoperative Imaging in Renal Transplant Patients with Tertiary Hyperparathyroidism. World journal of surgery 2021. link 3 Dream S, Chen H, Lindeman B. Tertiary Hyperparathyroidism: Why the Delay?. Annals of surgery 2021. link 4 Yang RL, Freeman K, Reinke CE, Fraker DL, Karakousis GC, Kelz RR et al.. Tertiary hyperparathyroidism in kidney transplant recipients: characteristics of patients selected for different treatment strategies. Transplantation 2012. link 5 Pajda M, Matug A, Widłak M, Antoniak K, Ficek R, Chudek J et al.. Influence of parathyroidectomy on blood pressure and function of the transplanted kidney in patients with tertiary hyperparathyroidism. Annals of transplantation 2006. link
5 papers cited of 6 indexed.